​

Elevance Health (ELV) Stock Forecast, Price Target & Predictions


OverviewRevenueOwnershipFinancialsChartTranscripts

ELV Stock Forecast


Elevance Health (ELV) stock forecast, based on 38 Wall Street analysts, predicts a 12-month average price target of $472.21, with a high of $523.00 and a low of $395.00. This represents a 8.82% increase from the last price of $433.93.

$250 $310 $370 $430 $490 $550 High: $523 Avg: $472.21 Low: $395 Last Closed Price: $433.93

ELV Stock Rating


Elevance Health stock's rating consensus is Buy, based on 38 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 27 Buy (71.05%), 11 Hold (28.95%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 38 0 11 27 Strong Sell Sell Hold Buy Strong Buy

ELV Price Target Upside V Benchmarks


TypeNameUpside
StockElevance Health8.82%
SectorHealthcare Stocks 15.45%
IndustryHealthcare Plans Stocks16.45%

Price Target Trends


1M3M12M
# Anlaysts111358
Avg Price Target$482.45$479.69$431.74
Last Closing Price$433.93$433.93$433.93
Upside/Downside11.18%10.55%-0.50%
Ratings Trends

DateStrong BuyBuyHoldSellStrong SellTotal
Nov, 263127--22
Oct, 262128--22
Sep, 263127--22
Aug, 263127--22
Jul, 262128--22
Analyst Price Target Forecasts

DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Nov 18, 2026David ToungArgus Research$510.00$421.5021.00%17.53%
Oct 23, 2026Piper Sandler$520.00$442.8517.42%19.83%
Oct 23, 2026Ann HynesMizuho Securities$490.00$445.2810.04%12.92%
Oct 23, 2026Goldman Sachs$451.00$445.281.28%3.93%
Oct 22, 2026UBS$523.00$439.1019.11%20.53%
Oct 22, 2026RBC Capital$455.00$441.213.13%4.86%
Oct 22, 2026Jason CassorlaGuggenheim$485.00$434.1311.72%11.77%
Oct 22, 2026Robert W. Baird$406.00$434.13-6.48%-6.44%
Oct 22, 2026Barclays$472.00$434.138.72%8.77%
Oct 12, 2026Jason CassorlaGuggenheim$460.00$412.7011.46%6.01%
Analyst Rating Forecasts

DateCompanyPrevious RatingNew RatingRating Change
Oct 27, 2026Wells FargoOverweightOverweighthold
Oct 23, 2026BernsteinOutperformOutperformhold
Oct 23, 2026Cowen & Co.BuyBuyhold
Oct 23, 2026Goldman SachsNeutralNeutralhold
Oct 22, 2026RBC CapitalSector PerformSector Performhold
Oct 22, 2026Bank of America SecuritiesBuyBuyhold
Oct 12, 2026GuggenheimBuyBuyhold
Oct 09, 2026Cantor FitzgeraldOverweightOverweighthold
Oct 07, 2026BarclaysOverweightOverweighthold
Jul 16, 2026Goldman SachsNeutralNeutralhold

Financial Forecast


EPS Forecast

$20 $29 $38 $47 $56 $65 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28 Dec 29
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28Dec 29
Reported$25.25$24.56$25.38$25.81$25.18----
Avg Forecast$25.94$29.02$33.07$33.21$34.49$39.12$45.09$53.01$60.81
High Forecast$26.78$29.93$33.17$33.39$35.31$43.70$46.79$55.16$63.27
Low Forecast$24.92$27.99$33.01$32.43$31.08$34.75$42.00$50.33$57.73
Surprise %-2.66%-15.37%-23.25%-22.28%-26.99%----

Revenue Forecast

$100B $140B $180B $220B $260B $300B Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28 Dec 29
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28Dec 29
Reported$138.64B$156.59B$171.34B$176.81B$199.13B----
Avg Forecast$137.85B$156.30B$170.38B$175.83B$191.75B$205.47B$221.23B$241.40B$279.48B
High Forecast$141.29B$160.07B$171.02B$177.24B$196.06B$217.15B$222.36B$248.91B$288.17B
Low Forecast$133.66B$152.01B$169.32B$174.23B$183.87B$194.40B$220.09B$232.01B$268.60B
Surprise %0.57%0.19%0.56%0.56%3.85%----

Net Income Forecast

$0 $3B $6B $9B $12B $15B Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28 Dec 29
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28Dec 29
Reported$6.10B$5.89B$5.99B$5.98B$5.66B----
Avg Forecast$5.67B$6.08B$5.99B$7.67B$7.74B$9.14B$10.35B$12.36B$14.17B
High Forecast$6.81B$7.30B$7.18B$7.78B$8.23B$10.19B$10.91B$12.86B$14.75B
Low Forecast$4.54B$4.87B$4.79B$7.56B$7.24B$8.10B$9.79B$11.73B$13.46B
Surprise %7.56%-3.08%--22.05%-26.82%----

ELV Forecast FAQ


Is Elevance Health stock a buy?

Elevance Health stock has a consensus rating of Buy, based on 38 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 27 Buy, 11 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that Elevance Health is a favorable investment for most analysts.

What is Elevance Health's price target?

Elevance Health's price target, set by 38 Wall Street analysts, averages $472.21 over the next 12 months. The price target range spans from $395 at the low end to $523 at the high end, suggesting a potential 8.82% change from the previous closing price of $433.93.

How does Elevance Health stock forecast compare to its benchmarks?

Elevance Health's stock forecast shows a 8.82% upside, underperforming the average forecast for the healthcare stocks sector (15.45%) and underperforming the healthcare plans stocks industry (16.45%).

What is the breakdown of analyst ratings for Elevance Health over the past three months?

  • November 2026: 13.64% Strong Buy, 54.55% Buy, 31.82% Hold, 0% Sell, 0% Strong Sell.
  • October 2026: 9.09% Strong Buy, 54.55% Buy, 36.36% Hold, 0% Sell, 0% Strong Sell.
  • September 2026: 13.64% Strong Buy, 54.55% Buy, 31.82% Hold, 0% Sell, 0% Strong Sell.

What is Elevance Health’s EPS forecast?

Elevance Health's average annual EPS forecast for its fiscal year ending in December 2026 is $39.12, marking a 55.36% increase from the reported $25.18 in 2025. Estimates for the following years are $45.09 in 2027, $53.01 in 2028, and $60.81 in 2029.

What is Elevance Health’s revenue forecast?

Elevance Health's average annual revenue forecast for its fiscal year ending in December 2026 is $205.47B, reflecting a 3.18% increase from the reported $199.12B in 2025. The forecast for 2027 is $221.23B, followed by $241.4B for 2028, and $279.48B for 2029.

What is Elevance Health’s net income forecast?

Elevance Health's net income forecast for the fiscal year ending in December 2026 stands at $9.14B, representing an 61.50% increase from the reported $5.66B in 2025. Projections indicate $10.35B in 2027, $12.36B in 2028, and $14.17B in 2029.